CSIMarket


Chemomab Therapeutics Ltd   (CMMB)
Other Ticker:  
 


 

Chemomab Therapeutics Ltd

CMMB's Financial Statements and Analysis



Chemomab Therapeutics Ltd reported in the first quarter of 2023 net earnings per share of $0.04 an increase by 81.82 % year on year from $0.02 and decline of 9.35 % from $0.04 earned in IV. Quarter (Dec 31 2022).


first quarter of 2023
Earnings Per Share Revenues
$ 0.04 $  0 Mill
$+0.02     +81.82 % Unch.    



Chemomab Therapeutics Ltd 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.


Chemomab Therapeutics Ltd is

More on CMMB's Income Statement



Chemomab Therapeutics Ltd 's net income of $8.753 million in the first quarter of 2023 increased by 71.49 % from net earnings of $5.104 million achieved in I. Quarter a year ago.

Sequentially net earnings grew by 5.81 % from net income of $8.272 million realized in previous quarter.

More on CMMB's Growth

Chemomab Therapeutics Ltd Inventories
CMMB's Cash flow In the first quarter of 2023 company's net cash flow was $7 million, capital expenditures grew by -0.014-92.86%, to $0 millions compare to same quarter a year ago

More on CMMB's Cash flow Statement


Chemomab Therapeutics Ltd does not pay out common stock dividend.

In trailing twelve-month period Chemomab Therapeutics Ltd payed $ -0.11 cash per share, on a free-cash flow basis .

Book value fell by -20.21 % sequentially to $0.13 per share.
Tangible Book value fell to $ 0.13 per share from $ 0.16.

Company repurchased 7.48 million shares or 3.28 % in Mar 31 2023.


More on CMMB's Dividends

 Market Capitalization (Millions) 166
 Shares Outstanding (Millions) 221
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 9




Chemomab Therapeutics Ltd does not pay out common stock dividend.

In trailing twelve-month period Chemomab Therapeutics Ltd had negative $ -0.11 cash flow per share, on a free-cash flow basis .

Book value fell by -20.21 % sequentially to $0.13 per share.
Tangible Book value fell to $ 0.13 per share from $ 0.16.

Company repurchased 7.48 million shares or 3.28 % in Mar 31 2023.


More on CMMB's Balance Sheets

 Market Capitalization (Millions) 166
 Shares Outstanding (Millions) 221
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 9
   


  News about Chemomab Therapeutics Ltd Earnings

Chemomab Therapeutics Ltd Surges with 77.93% Return on Equity in Q1 2023, Outperforming Industry Leaders

Chemomab Therapeutics Ltd Delivers Impressive Q1 2023 Results, ROE Increases to 77.93%
Chemomab Therapeutics Ltd, a leading pharmaceutical company, has announced its first quarter 2023 financial results, showcasing an incredible return on equity (ROE) of 77.93%. This figure is significantly above CMMB's average ROE of 2.42%, demonstrating the company's commitment to generating better profits for its investors.
The impressive ROE is a substantial improvement from 58.23% in the previous quarter, driven by growth in net income. In the major pharmaceutical preparations industry, Chemomab Therapeutics Ltd ranks fifth in terms of ROE...


Date modified: 2023-05-14T09:50:20+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com